GLPG 1205

Drug Profile

GLPG 1205

Alternative Names: GLPG-1205

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Galapagos NV
  • Class Anti-inflammatories
  • Mechanism of Action GPR84 protein antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Inflammatory bowel diseases
  • Discontinued Ulcerative colitis

Most Recent Events

  • 20 Jun 2017 Galapagos plans a clinical trial in undisclosed indication in late 2017
  • 06 Apr 2017 Phase-I development is ongoing in Belgium (NCT03102567)
  • 13 Feb 2017 Galapagos completes a phase I trial in Healthy volunteers in Belgium (NCT03102567)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top